Profits in the pipeline

Shares in German biotech MorphoSys firm could double as the royalties start to roll in, says Mike Tubbs.

918_MW_P34_Companies

MorphoSys's antibodies are used in a wide range of drugs.

Shares in this German biotech firm could double as the royalties start to roll in.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Swipe to scroll horizontally
MorphoSys (Frankfurt: MOR)
Share price€81.5Cash€450.5m
Market cap€2.5bnDividendn/a
Recent results2017 reported2018 guidanceChange (%)
Revenue€66.8m€67-72m+0.3%/+7.8%
EBIT (loss)(€67.6m)(€55-65m)-18.6%/-3.8%
R&D€99.1m€87-97m-13.9%/-2.1%
Dr Mike Tubbs

Highly qualified (BSc PhD CPhys FInstP MIoD) expert in R&D management, business improvement and investment analysis, Dr Mike Tubbs worked for decades on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing; knowledge which gave him a unique perspective on the stock markets.

Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development. He has been a contributor to MoneyWeek for many years, with a particular focus on R&D-driven growth companies.